Takinib
Cat. No.: IBDI-433259
Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC50=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (KD(app) of 0.46 μM).
Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution
Online Inquiry
Product Details
| Target |
MAP3K | Apoptosis |
| Molecular Weight |
322.36 |
| Appearance |
Solid |
| Synonyms |
EDHS-206 |
| SMILES |
CCCN1C2=CC=CC=C2N=C1NC(C3=CC(C(N)=O)=CC=C3)=O |
| Purity |
99.31% |
Storage & Handling
| Shipping |
Room temperature in continental US. May vary elsewhere. |
| Storage |
Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
